Tuberous sclerosis complex - review of the clinical - genetic, diagnostic and therapeutic aspects and analysis of a bulgarian pediatric population of 58 children – part II
Keywords:
neurocutaneous syndrome, Tuberous Sclerosis Complex, skin lesions, therapeutically-resistant epilepsy, mental retardation, tumors, TSC1 gene, TSC2 geneAbstract
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder, characterized by skin manifestations and formation of multiple tumors in different organs, mainly in the central nervous system due to mutation of one of the two tumor suppressor genes, TSC1 or TSC2, leading to impaired mTor kinase pathways. In several large studies, genotype-phenotype correlations have been examined with significant evidence regarding the characteristic clinical manifestation and disease course depending on the mutation in one of the two genes – a significantly more severe phenotype in patients with a TCS2 mutation than those with a mutation in the TSC1 gene. The aims of this publication is to provide an up-to-date review of the hitherto known clinical-genetic data, as well as to present the Bulgarian experience in 58 children and their families with TSC.
References
Bozhinova, V., Deneva, D., Tomov, V., Slavkova, E., Milanov, Iv. Tuberozna skleroza kompleks (TSC) – diagnostichni kriterii i pravila za prosledyavane i lechenie Chestota i klinichna kharakteristika na bŭlgarskite patsienti s TSC. Pediatriya, 2015, 55, 1, 26-30.
Bozhinova, V., Koleva, M. Terapevtichni vŭzmozhnosti i rezultati ot klinichnata praktika na patsienti s kompleks Tuberozna skleroza. Profilaktika, diagnostika i terapiya v det·sko-yunosheskata vŭzrast. 2019, 91-116.
Koleva, M., Bozhinova, V., Deneva, D., Glushkova, M., Todorov, T. i sŭavt. Genotip-fenotipni korelatsii pri bŭlgarskite patsienti s tuberozna skleroza. Bŭlgarska nevrologiya. 2019, 19, 3, 105-110.
Au, KS., Williams, AT., Roach, ES., Batchelor, L., Sparagana, SP., Delgado, MR. et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007, 9, 88-100.
Bolton, PF., Clifford, M., Tye, C., Maclean, C., Humphrey, A., le Marechal, K., Higgins, JNP., Neville, BGR., Rijsdjik, F., The Tu be - rous Sclerosis 200 Study Group, Yates JRW. Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study. Psychol Med. 2015, 45, 2321-31.
Choi, JE., Chae, JH., Hwang, YS., Kim, KJ. Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex. Brain Dev. 2006, 28, 440-446.
Curatolo, P., Porfirio, MC., Manzi, B., Seri, S. Autism in tuberous sclerosis. Europ. Journal of Ped. Neurology. 2004, 8, 327-332.
Dabora, SL., Jozwiak, S., Franz, DN., Roberts, PS., Nieto, A., Chung, J. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001, 68, 64-80.
de Vries, PJ., Whittemore, VH., Leclezio, L., Byars, AW., Dunn, D., Ess, KC. et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol. 2015, 52, 25-35.
Franz, DN., Belousova, E., Sparagana, S. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013 Jan 12, 381, 125-132.
Glushkova, M., Bojinova, M., Koleva, M., Dimova, P. et al. Molecular-genetic diagnostics of Tuberous sclerosis complex (TSC) in Bulgaria: six novel mutations in the TSC1 and TSC2 genes. Journal of Genetics. 2018, Vol. 97, 2, 419-427.
Jansen, AC., Sancak, O., D'Agostino, MD. et al. Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. Ann Neurol. 2006, 60, 528-539.
Jones, AC., Shyamsundar, MM., Thomas, MW., Maynard, J., Idziaszczyk, S., Tomkins, S., Sampson, JR., Cheadle, JP. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999, 64, 1305-1315.
Kingswood et al. Tuberous sclerosis registry to increase disease awareness (TOSCA) – baseline data on 2093 patients. Orphanet journal of rare diseases. 2017, 12, 2, 1-13, 3.
Krueger, DA., Care, MM., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, KA., Byars, A., Sahmoud, T., Franz, DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010, 363, 1801-1811.
Monteiro, T. et al. Tuberous sclerosis: Clinical characteristics and their relationship to genotype/phenotype. Anales de pediatria. 2014, 1, 5, 289-296.
Numis, AL., Major, P., Montenegro, MA., Muzykewicz, DA., Pulsifer, MB., Thiele, EA. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology. 2011, 76, 981-987.
Overwater et al. Genotype and brain pathology phenotype in children with tuberous sclerosis complex. European journal of human genetics. 2016, 1-8.
Rosset, C. et al. Molecular analisys of TSC1 and TSC2 gene s and phenotypic correlations in Brazilian families with tuberous sclerosis. Plos One. 2017, 12, 10.
Sancak, O., Nellist, M. et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005, 13, 731-741.
Zilbovicius, M., Boddaert, N. et al. Temporal lobe disfunction in childhood autism: A PET study. The American Journal of Psychiatry. 2000, 157, 12, 1988-1993.
Downloads
Published
How to Cite
Issue
Section
ARK
License
Copyright (c) 2020 Bulgarian Neurology
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
